Amphastar Pharmaceuticals (AMPH) Non Operating Income (2013 - 2026)

Amphastar Pharmaceuticals has reported Non Operating Income for 14 years, with the latest figure at -$1.2 million in Q2 2026.

• On a quarterly basis, Non Operating Income rose 58.41% year-over-year to -$1.2 million in Q2 2026; TTM through Jun 2026 was -$12.3 million, a 38.16% increase from a year earlier, with the FY2025 full-year figure at -$16.8 million, down 7.18% from the prior year.
• Non Operating Income was -$1.2 million for Q2 2026 at Amphastar Pharmaceuticals, up from -$3.6 million in the prior quarter.
• The five-year high for Non Operating Income was $7.4 million in Q1 2022, with the low at -$12.6 million in Q4 2023.
• Average Non Operating Income over 5 years is -$3.0 million, with a median of -$3.2 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income soared 242.89% in 2022, then tumbled 4699.25% in 2025.
• Over 5 years, Non Operating Income stood at $3.4 million in 2022, then tumbled by 468.58% to -$12.6 million in 2023, then soared by 90.65% to -$1.2 million in 2024, then sank by 212.35% to -$3.7 million in 2025, then surged by 67.9% to -$1.2 million in 2026.
• The last three Non Operating Income figures came in at -$1.2 million (Q2 2026), -$3.6 million (Q1 2026), and -$3.7 million (Q4 2025), per Business Quant data.